New Delhi (NVI): India is planning to produce about 300 million doses of the Russian Sputnik V COVID-19 vaccine in 2021, CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev announced.
“In India, we have agreements with four large manufacturers. India will produce about 300 mln doses or more of the vaccine for us next year,” Russia’s Tass news agency quoted Dmitriev as saying.
The agency further said, Dmitriev noted that, out of 110 production sites that negotiated production of Russian COVID-19 vaccine, RDIF chose 10 that meet its requirements.
“The Russian Sputnik V will be actively produced in the world and we see that this is built on a safe platform based on the human adenovirus,” he added.
Moreover, the Russian Embassy in India, quoting the RDIF CEO also said that Russia is testing the first samples of its Sputnik V vaccine against COVID-19 that were produced in India.
Dmitriev earlier said that production of Sputnik V has began in other countries, in particular in India, Korea, Brazil, and China, as per the reports.
In November, RDIF and pharma firm Hetero had agreed to produce over 100 million doses per year of the Sputnik V vaccine in India.
On August 11, Russia became the first country in the world to register Sputnik V coronavirus vaccine developed by the Gamaleya Center. However, the drug passed clinical trials in June-July.
-RJV
